Determinatin of Aldose Reductase (AR) activity in Diabetic Patients
Article Sidebar
Main Article Content
Abstract
The current study included estimation of Aldose reductase (AR) activity in serum of diabetic patients. The study included (47) samples of seram from diabetic patients serum (both types I and II), the patients age ranged from (9-80) years old, and (36) samples of seram from healthy people (control group) aged between (12-80) years old. The results showed significant elevation (P <0.05) in the AR activity in diabetic patients for both types compared with control group. The AR activity was (38.65 ±9.60) IU/ L in the serum of type II diabetes patients and (29.52 ± 5.75) IU/ L in patients with type I diabetes, compared to (11.01 ± 2.19) IU/ L in the serum of healthy people
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
2.World Health Organization Expert Committee (1999) "Definition Diagnosis and classification of diabetes mellitus and it's complication " Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva.
4. Ali, Y. S. and David, J. M. (2006) ″Screening for coronary disease in diabetes: when and how″ Clinical diabetes; 24:169 – 173.
5. Fowler, M. J. (2007) "Classification of diabetes :not all hyperglycemia is the same" Clinical diabetes; 25: 74 – 76.
6. Bell, R. H. and Hye, R. J. (1983) "Current research review animal models of diabetes mellitus:physiology and pathology" J. Surg. Res.; 35:433 – 460.
7. Kimmel, B. and Silvio, E. I. (2005) "Oral agents for typ 2 diabetes an update" Clinical diabetes ; 23(2): 64 – 76.
9. Smith, A.F, Beckett, G. J , Walker, S.W. and Rac, P.W.(1998) "Clinical Biochemistry" 6th ed, Blackwell Science :p317
10. Eleni , K. , Demopoulos ,V.J. (2013) ″ Structure – activity – selectivity relation on the keto – pyrrolyl – difluorophenol aldose reductase inhibitory scaffold ″ Pharmakeftiki ; 25(I) : 24-33 .
11. Sango, K., Kato, K., Tsukamoto, M., Niimi, N., Utsunomiya, K., et al. (2014) ″Physiological and Pathological Roles of Aldose Reductase in Schwann Cells ″ J Mol Genet Med S1: 012. doi:10.4172/1747-0862.S1-012
12. Howard, EI, Sanishvili, R, Cachau, RE, Mitschler, A, Chevrier, B, Barth, P, Lamour, V, Vanzandt, M, Sibley, E, Bon, C, Moras, D, Schneider, T , Joachimiak, A & Podjarny, A .(2004) . Ultrahigh resolution drug design 1: Details of interactions in human aldose reductase inhibitor complex at 0.66 + à. Proteins , 55 , 792 – 804 .
13. Markus, H.B., Raducha, M., Harris, H. (1983) ″Tissue distribution of mammalian aldose reductase and related enzymes″ Biochem Med ;29:31– 45.
14. Oates ,P.J.(2002) ″Polyol pathway and diabetic peripheral neuropathy″ Int Rev Neurobiol ;50:325–392.
15. Tanimoto, T., Maekawa, K., Okada, S., Yabe-Nishimura, C.(1998) ″ Clinical analysis of aldose reductase for differential diagnosis of the pathogenesis of diabetic complication″ Analytica Chimica Acta ;365:285–292.
16. Burrows, N. R., Li, Y., Geiss, L. S. (2010) "Incidence of reatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline" Diabetes Care; 33: 73 –7.
17. Zhang, X., Saaddine, J. B., Chou, C. F., Cotch, M. F., Cheng, Y. J., Geiss, L. S., et al(2010) "Prevalence of diabetic retinopathy in the United state ,2005-2008 " JAMA ; 304: 649 – 656.
18. van Heyningen, R.(1962) ″The sorbitol pathway in the lens″ Exp. Eye Res ; 7:396-404
19. Hayman ,S. & Kinoshita , J.H. (1965)″ Isolation and properties of lens aldose reductase ″ J. Biol. Chem ; 240:877-882 .
20. Kinoshita, J. H. (1965) ″Cataracts in galactosemia The Jonas S. Friedenwald memorial lecture ″ Invest. Ophthalmol ; 4:786-99 .
21. Chylack, L T., and Kinoshita, J. H.(1969) ″ A biochemical evaluation of a cataract induced in a high-glucose medium ″ Invest. Ophthalmol. ;8:401-12.
22. Winegrad, A. I., Morrison, A. D., and Clements, R. S.(1974)″ The polyol pathway: a model for biochemical mechanisms by which hyperglycemia may contribute to the pathogenesis of the complications of diabetes mellitus. In Diabetes″. Proc. 8th Congr. IDF. Malaisse, W. J., and Pirart, J., Eds. Amsterdam and New York, Excerpta Medica/ American Elsevier, pp. 387-95.
23. Gabbay , K.H. (1973)″The sorbitol pathway and the complications of diabetes ″N. Engl. Med; 288: 831-36 .
24. Hayman ,S. & Kinoshita, J.H. (1965)″ Isolation and properties of lens aldose reductase ″ J.Biol.Chem ; 240:877-882 .
25. Ohmure, C., Watada , H. ,Azuma, K., Shimizu, K. ,Kanazawa , A. ,Ikeda , f .,Yoshihara, T., Fujitani, Y., Hirose, T., Tanaka, y., and Kawamori, R. (2009) ″Aldose reductase inhibitor, epalrestat , reduces lipid hydroperoxidos in type 2 diabetes″, Endocrine Journal ; 56:149-156 .
26. Satyanarayana ,A. ,Reddy ,G .B , Balakrishna ,N. ,Ayyagari ,R., Padma, M., Viswanath, K., Petrash, J.M . (2008) ″Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy ″ Mol vis ; 14:593-601.
27. Gupta, S. K., Kalaiselvan, V., Srivastava, S., Saxena, R. & Agrawal, S. S. (2009) ″Inhibitory effect of Trigonella foenum-graecum on galactose induced cataracts in a rat model ″ in vitro and in vivo studies. J Ophthalmic Vis Res; 4(4):213 – 219
28. Kumar, C.S., Kumar, V.V., and Raju, T.N. (2010) ″Protective action of curcumin and vitamin E against the imbalance of electrolytes calcium , sodium and potassium in galactose – induced cataract″ Int .J.appl. Biology and Pharmaceutical Technology , Vol .1(1) pp.183-189.
29. Wu, R. R., Lyons, P. A., Wang , A., Sainsbury, A.J., Chung, S., and Palmer, T.N.(1993). ″Effects of galactose feeding on aldose – reductase gene expression .J.Clin. Invest ; 92 :155-159 .
30. Keenan, H. A., Costacou, T., Sun, J.K, Doria, A., Cavellerano, J., Coney, J., Orchard, T.J., Aiello, L.P., King , G.L. (2007) ″ Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration ″ the 50- year medalist study , Diabetes Care ; 30: 1995-1997.
31. Thomas , T. , Rauscher, F. ,Sanders , R., Veltman, J., and Watkins, J.B., (2000) ″Effect of aldose reductase inhibitors on antioxidant defense in ret and rabbit liver ″ Toxicological Sciences ; 53 :145-149 .
32. Akila, V., Prashant ,H., Harishchandra, Vivian Dsouza, Benedicta , D. Souza. ( 2007) "Age related changes in lipid per oxidation and antioxidant in elderly people" Indian J. Clinical Biochem; 22(1): 131-134.
33. Badger, A.M., Hanldler, J. A., Genell. C.A., Herzyk, D., gore, E., polsky, R.,Webb, L. & bugelski, P.J.(1999) INT. J. Immuno. Pharmacol. ; 21:161.
34.-Dabrwska-Bouta, B., Struzynska, L. & Rafalowska, U.,(1996) Mol. Chem.Neuropathol., 29:127 .
35. Taraza, C., Mohra, M., Vargolici, B., Dinu, V., Rom. J.(1997) Intern. Med. ; 35:89.
36. Ernst, P.,(1999) Am. So. Nutr. Sci. ; 147:9625 .
37. Strubelt-O., Kremer- J, Tilse-A., Keogh- J, Pentz-R., Younes- M J.(1996) Toxicol–Environ-Health. Feb.23: 47(3): 267-83.